Advertisement

Topics

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

13:24 EST 12 Feb 2018 | SCRIP

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former...

      

Related Stories

 

Original Article: Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...